Online Supplement

Mitochondrial DNA Copy Number Variation in Asthma Risk and Severity

Weiling Xu¹, Yun Soo Hong², Bo Hu³, Suzy A. A. Comhair¹, Allison J. Janocha¹, Joe G. Zein⁴, Ruoying Chen³, Deborah A. Meyers⁵, David T. Mauger⁶, Victor E. Ortega⁷, Eugene R. Bleecker⁵, Mario Castro⁸, Loren C. Denlinger⁹, John V. Fahy¹⁰, Elliot Israel¹¹, Bruce D. Levy¹¹, Nizar N. Jarjour¹², Wendy C. Moore¹³, Sally E. Wenzel¹⁴, Benjamin Gaston¹⁵, Chunyu Liu¹⁶, Dan E. Arking^{2*}, Serpil C. Erzurum^{1, 3*} for the National Heart, Lung, and Blood Institute (NHLBI) Severe Asthma Research Program (SARP) and TOPMed mtDNA Working Group in NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium

Table of Contents

1.	UKB dataset, methods, and supplementary Tables E1 and E2	3
2.	SARP dataset	9
3.	Adjusted mtDNA-CN and analysis	.10
4.	Supplementary Tables E3 – E6	.11
5.	Supplementary Figures E1 – E2	.15

Supplementary Methods

Supplementary UKB Dataset Methods I. <u>UKB curated dataset criteria</u>

The UK Biobank (UKB) dataset includes 502,485 participants (54.4% female, 12.1% prevalent asthma) with age range 37–73 years (mean \pm SD, Male 56 \pm 8, Female 56 \pm 8) recruited between 2006 and 2010 throughout the UK across 22 assessment centers. Exclusion reasons were non-Whites (N = 28,910), related individuals (N = 78,660), cell count missing (N = 12,022), cell count outliers (N = 3,667), exclusion criteria (N = 96,787), without medication information (*n* = 53), and those who were not genotyped (N = 13,460)

Inclusion criteria. We include asthmatics and controls (non-asthmatic).

Cell count outliers are excluded due to known influence on mtDNA-CN (E1). For mtDNA-CN analyses, we excluded those who are outliers by cell counts as shown below as previously described (E1).

Cell count and platelets volume and size outliers were excluded.

Excluded OutliersLog(WBC) ≤ 1.25 or ≥ 3 [WBC ≤ 3.49 or ≥ 20.08 K/ul]Log(RBC) ≤ 1.4 or ≥ 2 [RBC ≤ 4.0 or $\geq 7.3 \times 10^{6}$ /ul]Platelet ≤ 10 or ≥ 500 Log(Lymphocyte) ≤ 0.10 or ≥ 2 [Lymphocyte ≤ 1.1 or ≥ 7.3 K/ul]Log(Mono) ≥ 0.9 [Mono ≥ 2.4 K/ul]Log(Neutrophil) ≤ 0.75 or ≥ 2.75 [Neutrophil ≤ 2.1 or ≥ 15.6 K/ul]Log(Baso) ≥ 0.45 [Baso ≥ 1.5 K/ul]

Exclusion criteria specific to this study:

- a. Exclusion criteria:
 - 1. Current smokers
 - 2. Prevalent cancer
 - 3. Prevalent chronic obstructive pulmonary disease (COPD)
 - 4. Cystic fibrosis (CF)
 - 5. Gastro-oesophageal reflux disease (GORD, GERD)
 - 6. Chronic sinusitis
 - 7. Sleep apnea
 - 8. Renal/kidney failure
 - 9. Hepatic failure
 - 10. Heart failure
- b. In the UKB to find these to exclude, we used ICD9 code(s), ICD10 code(s), self-report code(s), and Data-Field(s) (see Table E1).

Table E1. UKB ICD9 code(s), the	ICD10 code(s), self-report co	ode(s) and Data-Field	(s) of exclusion criteria
			()

#	Comorbidity	ICD9	ICD10	Self-Reported Codes	Data-Field
1	Current smokers	Not reported		Not reported	20116 Smoking status (<i>n</i> =55687)
2	Prevalent cancer	Not reported	Not reported	Not reported	40005 Date of cancer diagnosis before study entry date (field: 53) (<i>n</i> =89765)
3	COPD				
4	CF	Not reported	E84.0 Cystic fibrosis with pulmonary manifestations (<i>n</i> =16) J84.0 Alveolar and parietoalveolar conditions (<i>n</i> =22) J84.1 Other interstitial pulmonary diseases with fibrosis (<i>n</i> =2703) J84.8 Other specified interstitial pulmonary	1121 pulmonary fibrosis 1115 interstitial lung disease 1122 fibrosing alveolitis/unspecified alveolitis	

diseases (n=115)

			J84.9 Interstitial		
			pulmonary disease,		
			unspecified (<i>n</i> =958)		
5	GERD	53010 Oesophageal	K21.0 Gastro-	1138 gastro-oesophageal	
		mention of	disease with	reflux	
		oesonhagitis	oesophagitis	Tellux	
		(<i>n</i> =8)	(<i>n</i> =18782)		
		53011 Oesophagitis	K21.9 Gastro-		
		(with oesophageal	oesophageal reflux		
		reflux) (<i>n</i> =12)	disease without		
			oesophagitis		
	Ohmensie		(<i>n</i> =37933)		
6	Chronic	4730 Chronic sinusitis,	J32.0 Chronic maxiliary	1416 chronic sinusitis	
	Sinusius	4731 Chronic sinusitis	.132 1 Chronic frontal		
		frontal (<i>n</i> =5)	sinusitis (<i>n</i> =73)		
		4732 Chronic sinusitis,	J32.2 Chronic ethmoidal		
		ethmoidal (n=13)	sinusitis (<i>n</i> =216)		
		4733 Chronic sinusitis,	J32.3 Chronic		
		sphenoidal (n=1)	sphenoidal sinusitis		
		4/38 Other specified	(<i>n</i> =45)		
		(n-2)	J32.4 Unronic		
		4739 Chronic sinusitis	J32.8 Other chronic		
		unspecified	sinusitis (<i>n</i> =263)		
		(<i>n</i> =185)	J32.9 Chronic sinusitis,		
		· · · ·	unspecified		
			(<i>n</i> =3017)		
7	Sleep apnea	Not reported	G47.3 Sleep apnea	1123 sleep apnea	
	Devel/Iside est		(<i>n</i> =9647)		
8	Renal/kidney	foilure (n=18)	N 18.0 End-stage renai	1192 renal/kidney failure	ESRD as defined by
	lanule	5869 Renal failure	N18 1 Chronic kidney	dialysis	ORD. (11-101)
		unspecified (<i>n</i> =9)	disease. stage 1	1194 renal failure not	
			(<i>n</i> =187)	requiring dialysis	
			N18.2 Chronic kidney		
			disease, stage 2		
			(<i>n</i> =1350)		
			(n=10462)		
			N18 4 Chronic kidney		
			disease. stage 4		
			(<i>n</i> =1487)		
			N18.5 Chronic kidney		
			disease, stage 5		
			(n=1248)		
			ropal failuro (n=73)		
			N18.9 Chronic renal		
			failure, unspecified		
			(<i>n</i> =9095)		
			N19 Unspecified renal		
		5740 AL L I	failure (<i>n</i> =2542)		
9	Hepatic	5712 Alconolic	K72.0 Acute and	1158 liver failure/cirrnosis	
	lanure	(n=1)	failure (n=246)		
		5714 Chronic hepatitis	K72.1 Chronic hepatic		
		(<i>n</i> =13)	failure (<i>n</i> =39)		
		5715 Cirrhosis of liver	K72.9 Hepatic failure,		
		without mention of	unspecified (n=739)		
		alcohol (<i>n</i> =4)	K/3.0 Chronic persistent		
		(n=7)	elsewhere classified		
		(n-r)	(n=2)		
			K73.1 Chronic lobular		
			hepatitis, not		
			elsewhere classified		
			(<i>n</i> =9)		

hepatitis, not elsewhere classified	
elsewhere classified	
(n-76)	
(1 - 10)	
K73.8 Other chronic	
hepatitis not	
elsewhere classified	
(n=22)	
K73.9 Chronic hepatitis.	
unspecified (<i>n</i> =149)	
K74.0 Hepatic fibrosis	
(<i>n</i> =331)	
K74.1 Hepatic sclerosis	
(n=29)	
K74.2 Hepatic fibrosis	
with hepatic	
sclerosis (<i>n</i> =7)	
K74.3 Primary biliary	
cirrhosis (n=393)	
K74.4 Secondary biliary	
cirrhosis ($n=24$)	
K74.5 Biliary cirrhosis,	
unspecified (n=134)	
K74.6 Other and	
unspecified cirrhosis	
of liver (<i>n</i> =1550)	
10 Heart failure 4280 Congestive heart 150.0 Congestive heart 1076 heart	
failure $(n=6)$ failure $(n=6650)$ failure/pulmonary	
4281 Left heart failure I50.1 Left ventricular odema	
(<i>n</i> =13) failure (<i>n</i> =8432)	
4289 Heart failure, I50.9 Heart failure,	
unspecified (<i>n</i> =2) unspecified	
(<i>n</i> =5701)	

*Count (*n*) for each item is included.

II. UKB lung function methods

Because many participants do not have calculated FEV1 % predicted, we are inputting predicted lung functions so we can analyze % FEV1. See **Table E2** below for coefficients from prediction equations and R Codes to calculate FEV1 and FVC percent predicted (E2) provided by Joe Zein.

 Table E2. Coefficients from prediction equations for normal lung function measures by sex.

	b ₀	b1	b 2	b3	
Corresponding variable	Intercept	Α	A^2	In H	Equation
In FEV1 L					
Males (R ² =0.59; σ=0.14)					
Mean					
Age ≤25 yrs	-10.41186	0.09569	-0.00221	2.10839	e ^{-10.41186 + 0.09569A -0.00221A² + 2.10839InH}
Age >25 yrs	-9.37674	0.00183	-0.00011	2.10839	e -9.37674 + 0.00183A - 0.00011A^2 + 2.10839In H
LLN					
Age ≤25 yrs	-10.75820	0.10320	-0.00231	2.10839	e ^{-10.75820 + 0.10320A - 0.00231A² + 2.10839In H}
Age >25 yrs	-9.72308	0.00933	-0.00021	2.10839	e ^{-9.72308 + 0.00933A - 0.00021A² + 2.10839In H}
Females (R ² =0.69; σ=0.14)					
Mean	-8.49717	0.00422	-0.00015	1.90019	e ^{-8.49717 + 0.00422A - 0.00015A² + 1.90019In H}
LLN	-8.68467	0.00495	-0.00018	1.90019	e ^{-8.68467 + 0.00495A - 0.00018A^2 + 1.90019In H}
In FVC L					
Males (R ² =0.52; σ=0.14)					
Mean					
Age ≤25 yrs	-11.45146	0.09895	-0.00216	2.32222	e ^{-11.45146 + 0.09895A - 0.00216A² + 2.32222ln H}
Age >25 yrs	-10.36706	0.00434	-0.00011	2.32222	e ^{-10.36706 + 0.00434A - 0.00011A² +2.32222ln H}
LLN					
Age ≤25 yrs	-11.63230	0.09795	-0.00217	2.32222	e ^{-11.63230 + 0.09795A - 0.00217A² + 2.32222ln H}
Age >25 yrs	-10.54790	0.00334	-0.00012	2.32222	e ^{-10.54790 + 0.00334A - 0.00012A² + 2.32222ln H}
Females (R ² =0.62; σ=0.15)					
Mean	-9.66999	0.00837	-0.00017	2.14118	e ^{-9.66999 + 0.00837A - 0.00017A² + 2.14118ln H}
LLN	-9.84941	0.00772	-0.00018	2.14118	e ^{-9.84941 + 0.00772A -0.00018A^2 + 2.14118In H}
In FEV1/FVC					

Males (R ² =0.15; σ=0.08)					
Mean	1.03981	-0.00394	0.00002	-0.21653	e ^{1.03981 - 0.00394A + 0.00002A² - 0.21653In H}
LLN	0.82621	0.00101	-0.00005	-0.21653	e ^{0.82621+0.00101A-0.00005A^2-0.21653In H}
Females (R ² =0.16; σ=0.08)					
Mean	1.15822	-0.00415	0.00002	-0.23815	e ^{1.15822 - 0.00415A + 0.00002A^2 - 0.23815In H}
LLN	1.00699	-0.00196	-0.00001	-0.23815	e ^{1.00699 - 0.00196A - 0.00001A^2 -0.23815In H}

Model: mean lung function=e^{b0+b1A+b2A^2+b3ln H}.

R²: fraction of explained variance; σ: SD of residuals; LLN: lower limit of normal; A: age; H: height.

A. Codes to extract percent predicted for FEV1 in the UKB.

Please find the codes Field 3063 and 3062 have 3 measurements that are used to calculate ATS reproducibility

Data-Field 3063 Description: Forced expiratory volume in 1-second (FEV1)

Data-Field 20150 = "FEV1" Description: Forced expiratory volume in 1-second (FEV1), Best measure

Data-Field 3062 Description: Forced vital capacity (FVC)

Data-Field 20151 = "FVC" Description: Forced vital capacity (FVC), Best measure

Data-Field 20152 Description: Reproducibility of spirometry measurement using ERS/ATS criteria

Data-Field 21003 Description: Age when attended assessment center

Data-Field 21022 Description: Age at recruitment

Data-Field 50 Description: Standing height

Data-Field 31 Description: Sex

Data-Field 21000 Description: Ethnic background

Data-Field 20255 Description: Spirometry QC measure

B. R Codes to calculate FEV1 and FVC percent predicted.

function to identify max FEV1
uk.b\$FEV1_max <- apply(FEV1_merged, 1, function(x){
 max(x,na.rm = T)
})</pre>

#change -Inf to NA uk.b\$FEV1_max[uk.b\$FEV1_max == -Inf] <- NA

```
# merging all fvc measurements
FVC merged <- cbind(uk.b$Forced vital capacity FVC, uk.b$Forced vital capacity FVC 2,
          uk.b$Forced vital capacity FVC 3)
dim(FVC_merged)
# function to identify max FVC
uk.b$FVC_max <- apply(FVC_merged, 1, function(x){
max(x,na.rm = T)
})
#change -Inf to NA
uk.b$FVC max[uk.b$FVC max == -Inf] <- NA
head(FVC_merged,10)
#dput(names(uk))
#3 - Step 3: Define Predicted FEV1
# FEV1 Predicted values calculated from max 3 visits according to UKB formula
uk$FEV1pred<- exp(ifelse(uk$Sex ==1 & uk$age <=25, (-10.41186 + 0.09569*uk$age - 0.00221*uk$age*uk$age +
(2.10839*(log(uk$Standing_height)))),
            ifelse(uk$Sex ==1 & uk$age > 25, (-9.37674 + 0.00183*uk$age - 0.00011*uk$age*uk$age +
(2.10839*(log(uk$Standing_height)))),
                ifelse(uk$Sex ==0, (-8.49717 + 0.00422*uk$age - 0.00015*uk$age*uk$age +
(1.90019*(log(uk$Standing height)))),
                    NA))))
describe(uk$FEV1pred)
# Percent predicted from MAXIMUM FEV1 Calculated
uk$fev1pp cal <- round((uk$FEV1 max/uk$FEV1pred*100), 2)
uk$fev1pp cal[1:10]
#4 - Step 4: Define Predicted FVC
uk$FVCpred<- exp(ifelse(uk$Sex ==1 & uk$age <=25, (-11.45146 + 0.09895*uk$age - 0.00216*uk$age*uk$age +
(2.32222*(log(uk$Standing_height)))),
            ifelse(uk$Sex ==1 & uk$age > 25, (-10.36706 + 0.00434*uk$age - 0.00011*uk$age*uk$age +
(2.32222*(log(uk$Standing height)))),
                ifelse(uk$Sex ==0, (-9.66999 + 0.00837*uk$age - 0.00017*uk$age*uk$age +
(2.14118*(log(uk$Standing_height)))),
                    NA))))
describe(uk$FVCpred)
## Percent predicted from MAXIMUM FVC Calculated
uk$fvcpp_cal <- round((uk$FVC_max/uk$FVCpred*100), 2)
uk$fvcpp_cal[1:10]
```

III. Define mild, moderate-severe asthma in the UKB.

ii. medication

Asthmatics were defined based on self-report. Moderate-severe asthma or mild asthma was defined by asthma medication use based on the UKB id codes among self-reported asthma patients (E3).

The definition for asthma and severity

b.

a. For a binary yes/no

Asthma: self-reported asthma regardless of use of asthma-related medication Non-asthma: absence of self-reported asthma regardless of use of asthma-related

For asthma severity

 $\dot{\rm i}.$ Moderate-severe asthma: self-reported asthma AND on medication for moderate-severe asthma (see below)

ii. Mild asthma: self-reported asthma AND on any medication for asthma, excluding medication for moderate-severe asthma

iii. Non-asthma: absence of self-reported asthma regardless of use of asthma-related medication (so even if he/she is on medication for mild or severe asthma, this person would be defined as not having asthma)

1140883548 ipratropium 1141182628 tiotropium 1140855320 isoetharine hydrochloride* 1140855322 numotac 10mg m/r tablet 1140855328 aleudrin 20mg tablet** 1140855330 aleudrin 1% spray for nebuliser** 1140855332 iso-autohaler 80micrograms inhaler** 1140855358 theodrox tablet 1140855360 sabidal sr-270 424mg m/r tablet 1140855366 pro-vent 300mg m/r capsule 1140855400 bronchodil 20mg tablet 1140855424 theograd 350mg m/r tablet 1140855426 biophylline 350mg m/r tablet 1140855442 adrenaline+atropine compound spray 1140855496 alupent expectorant 20mg tablet* 1140855504 bricanyl compound tablet 1140855506 bricanyl expectorant elixir 1140855530 nethaprin dospan m/r tablet 1140855540 tedral tablet 1140855542 tedral elixir 1140855540 tedral tablet 1140855542 tedral elixir 1140862092 maxivent 100micrograms inhaler 1140862144 salmeterol 1140862148 serevent 25mcg inhaler 1140862162 bricanyl 5mg tablet 1140862168 bricanyl 250mcg inhaler 1140862222 brelomax 2mg tablet 1140862224 respacal 2mg tablet 1140862236 atrovent 20micrograms inhaler 1140862260 aminophylline 1140862266 phyllocontin continus 225mg m/r tablet 1140862274 pecram 225mg m/r tablet 1140862280 bambec 10mg tablet 1140862290 adrenaline product 1140862292 medihaler-epi 280micrograms inhaler 1140862294 adrenaline acid tartrate 280micrograms inhaler 1140862306 cam 4mg/5ml s/f mixture 1140862310 medihaler-iso 80micrograms inhaler 1140862320 alupent 20mg tablet* 1140862336 amnivent 225 sr m/r tablet 1140862346 choline theophyllinate 1140862348 choledyl 100mg tablet 1140862362 duovent inhaler 1140862364 franol tablet 1140862374 ephedrine hydrochloride+theophylline 11mg/120mg tablet 1140862412 theophylline product 1140862414 nuelin 125mg tablet 1140862418 lasma 300mg m/r tablet 1140862424 slo-phyllin 60mg m/r capsule 1140862432 theo-dur 200mg m/r tablet 1140862438 uniphyllin continus 200mg m/r tablet 1140862474 aerobec 50mcg autohaler 1140868364 prednisone 1140868370 decortisyl 5mg tablet 1140881862 oxivent 100mcg inhaler 1141157264 salmeterol product 1141157402 prednisolone product 1141173346 cortisone 1141176832 seretide 50 evohaler 1141182632 spiriva 18micrograms inhalation capsule 1141195224 formoterol 1141195232 budesonide+formoterol 1141157126 montelukast product 1141157132 singulair 10mg tablet 1141168340 zafirlukast 1141168344 accolate 20mg tablet

Medications identifying moderate-severe asthma including the UKB id code (E3).

Supplementary SARP Dataset Methods

Asthmatic participants

1882 samples with sequencing data were from Trans-Omics for Precision Medicine (TOPMed). We include both non-severe and severe asthmatics. Exclusion criteria of SARP study of TOPMed included having any of the following: current smokers (more than 5-10 pack years depending on age), other respiratory diseases (e.g., cystic fibrosis or chronic obstructive pulmonary disease), premature birth before 35 weeks' gestation, clinically relevant or untreated gastroesophageal reflux, recurrent sinopulmonary infections or obstructive sleep apnea, and cancer diagnosis in the past five years. Exclusion reasons for this study were without matched IDs in the phenotype dataset (N = 144), without severity information (N = 151), missing one row of DNA position (N = 1), duplicate subjects (N = 2), healthy controls (N = 5), age less than 18 years (N = 291), and blood cell count outlier (N = 5).

For SARP participants, asthma was verified based upon American Thoracic Society guidelines, which include positive methacholine challenge test and/or reversible airflow obstruction. The severity of asthma was classified as severe and non-severe in SARP I & II according to the initial ATS workshop definition of severe asthma (E4) and in SARP III based on American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines (E5).

I. SARP dataset cleaning

- A. Inclusion criteria. We include asthmatics including non-severe and severe asthmatics.
- B. Exclusion criteria of SARP study of TOPMed:
 - a. Current smokers (more than 5-10 pack years depending on age)
 - b. Cancer diagnosis in the past five years
 - c. Other respiratory diseases [e.g., cystic fibrosis (CF) or chronic obstructive pulmonary disease (COPD)]
 - d. Premature birth before 35 weeks' gestation
 - e. Clinically relevant or untreated gastroesophageal reflux
 - f. Recurrent sinopulmonary infections
 - g. Obstructive sleep apnea
- C. Exclusion reasons for this study:
 - a. Without matched IDs in the phenotype dataset (N = 144)

and from 4 research centers, 2 of SARP I&II and 3 of SARP III

- b. Without severity information (N = 151)
- c. Missing one row of DNA position (N = 1)
- d. Duplicate subjects (N = 2)
 e. Healthy controls (N = 5)
- f. Age less than 18 years (N = 291)
- g. Five cell count outliers are identified using the IQR method or are excessively high or low based on clinical knowledge (WBC > 20.08 or < 3.49 x10⁹/liter; platelet > 500 or < 10 x10⁹/liter; lymphocyte > 7.3 or < 1.1 x10⁹/liter; monocyte > 2.4 x10⁹/liter; neutrophil > 15.6 or < 2.1 x10⁹/liter; basophil > 1.5 x10⁹/liter; eosinophil > 2.1 x10⁹/liter), which including 3 EA and 2 AA (all females, all severe asthmatics, and age range 29–54 years).
- D. Participants include 1283 asthmatics (66.3% female, 703 non-severe asthmatics, and 580 severe asthmatics) with age range 18–84 years (mean ± SD, Male 41 ± 14, Female 41 ± 14), who self-identify as European ancestry (EA, N = 838), African ancestry (AA, N = 339) or other ancestries (American Indian, Asian, Hawaiian and others, N = 106). SARP participants enrolled at 11 clinical research centers including 778 from SARP I & II and 505 from SARP III.

II. Creating the dataset of SARP.

FEV1 % predicted is ready to use in SARP.

Healthy control participants

Healthy control participants were enrolled in SARP I and II as a comparison group. All healthy control participants were over 18 years old, non-smokers, free of respiratory symptoms, and had normal spirometry, a negative methacholine challenge, and $F_ENO < 50$ ppb (E6). Any participants with measured F_ENO , SOD activity, or GPx activity were included in this analysis (Table E3). Two individuals were excluded (one SOD outlier, one F_ENO outlier).

Adjusted mtDNA-CN and Analysis

Because there is variation in mtDNA-CN methodology (Affymetrix Axiom array in the UKB as opposed to mtDNA/nDNA in TOPMed) and because depending on study, mtDNA-CNs and age, sex, and WBC counts measurement can vary, we evaluated the mtDNA-CN residual of each individual relative to the total population mean adjusting for confounding factors.

For the UKB data, as described previously (E1), given the known impact of age, sex, and cell counts on mtDNA-CN, we first used visual inspection to identify outliers for cell counts. We then excluded non-Whites, related individuals (used.in.pca.calculation=0), and cell count outliers and then adjusted for age, sex, and cell counts using a backwards regression, starting with a natural spline (df=4) for each covariate. The final model obtained was ("log_" indicates log-transformed variable):

 $\begin{array}{l} \textit{Unadjusted } \mathtt{mtDNA}_{\textit{CN}} = \mathtt{ns}(\mathtt{age}, \mathtt{df} = 4) + \mathtt{sex} + \mathtt{ns}(\mathtt{log}_\mathsf{WBC}, \mathtt{df} = 4) + \mathtt{ns}(\mathtt{log}_\mathsf{RBC}, \mathtt{df} = 4) + \mathtt{ns}(\mathtt{log}_\mathsf{Lymph}, \mathtt{df} = 4) + \mathtt{ns}(\mathtt{log}_\mathsf{Nutrophil}, \mathtt{df} = 4) + \mathtt{log}_\mathsf{Baso} + \mathtt{log}_\mathsf{NutrBC} \\ \end{array}$

Beta estimates from these analyses were then used to generate fitted values in the full UKB dataset using the 'predict' function. Adjusted mtDNA CN was derived as the residuals from the above model. For all analyses, the adjusted mtDNA-CN was further standardized by subtracting the mean and dividing by the standard deviation (mean 0 and standard deviation 1).

The difference (95% confidence intervals [CI]) in mtDNA-CN by presence of asthma and by asthma severity in the UKB was evaluated using linear regression models adjusted for age, age², sex, center, log-transformed neutrophil and eosinophil counts, and platelet counts:

 $\begin{aligned} Adjusted \ mtDNA_{CN} &= \ \beta_0 + \beta_1(asthma) + \beta_2(age) + \beta_3(age^2) + \beta_4(sex) + \beta_5I(center) \\ &+ \beta_6(\log neutrophil) + \beta_7(\log eosinophil) + \beta_8(platelet). \end{aligned}$

The relationship between mtDNA-CN and age was examined using the following linear models:

Unadjusted mtDNA_{CN} = $\beta_0 + \beta_1(age) + \beta_2(asthma) + \beta_3(age \times asthma)_1$

 $\begin{array}{l} \textit{Unadjusted mtDNA_CN} = \ \beta_0 + \beta_1(age) + \beta_2(asthma) + \beta_3(age \times asthma) + \beta_4(sex) + \beta_5 \textit{I}(center) + \beta_6(\log neutrophil) + \\ \beta_7(\log eosinophil) + \beta_8(platelet). \end{array}$

Another two models were fitted by replacing asthma presence (no / yes) with asthma severity (non-asthma / mild asthma / moderate-severe asthma) in the above two models.

For SARP data, the adjusted mtDNA-CN was derived as the residual from the following regression model:

Unadjusted $mtDNA_{CN} = cohort + age + age^2 + age * cohort + I(age^2) * cohort + sex + race + WBC + neutrophil.$

The adjusted mtDNA CN was also standardized as the analyses for the UKB data.

The difference (95% confidence intervals [CI]) in mtDNA-CN by asthma severity was evaluated using linear regression models adjusted for the same set of covariates in the above model for adjusted CN.

The relationship between mtDNA-CN and age was examined using the following linear models:

Unadjusted mtDNA_{CN} = $\beta_0 + \beta_1(age) + \beta_2(asthma severity) + \beta_3(age \times asthma severity)$

 $\begin{array}{l} \textit{Unadjusted mtDNA_CN} = \ \beta_0 + \beta_1(age) + \beta_2(asthma \ severity) + \beta_3(age \times asthma \ severity) + \beta_4(sex) + \beta_5 race + \beta_6 neutrophil + \\ \beta_7 \textit{WBC}. \end{array}$

Table E3. Features of asthmatics and healthy controls in SARP

Characteristics	Healthy Controls (<i>n</i> = 259)	Asthma (<i>n</i> = 1283)	<i>P</i> Value [*]
Age — yr	32 ± 11	42 ± 14	<.0001
Female — %	63	66	0.3
Ancestry — %			
European ancestry	73	65	0.01
African ancestry	17	26	0.0009
Body mass index — kg/m ²	26.5 ± 6.6	31.0 ± 8.4	<.0001
Blood pressure — mm Hg			
Systolic	119 ± 14	125 ± 15	<.0001
Diastolic	72 ± 9	76 ± 10	<.0001
Hemoglobin — g/dL	14.2 ± 2.7	14.3 ± 5.2	0.7
Hematocrit — %	41.1 ± 5.6	41.3 ± 4.6	0.5
Lung functions			
Forced expiratory volume in 1 second — % predicted	98 ± 10	74 ± 21	<.0001
Forced vital capacity —% predicted	99 ± 11	86 ± 18	<.0001
FEV ₁ /FVC	0.83 ± 0.07	0.70 ± 0.11	<.0001
White blood cells — x10 ⁹ /liter	6.1 ± 1.7	7.3 ± 2.5	<.0001
Neutrophils	3.7 ± 3.0	4.4 ± 2.2	0.001
Eosinophils	0.13 ± 0.11	0.27 ± 0.24	<.0001
IgE — IU/ml	73 ± 155	334 ± 700	<.0001
Glutathione peroxidase — U/ml	0.087 ± 0.020	0.087 ± 0.023	0.9
Superoxide dismutase — U/ml	22.3 ± 10.8	19.1 ± 10.7	0.003
Fractional exhaled nitric oxide — ppb	18 ± 14	36 ± 35	<.0001

Mean ± SD; *P value for asthmatics vs. healthy controls.

Table E4. Features of study participants in quantile (Q)4 and Q1 of adjusted mtDNA-CN in SARP

Characteristics	Q1 (<i>n</i> = 309)	Q4 (<i>n</i> = 310)	<i>P</i> Value [*]
Severe asthmatics — %	43.0	42.2	0.8
Age — yr Female — % Ancestry — %	39 ± 14 66	40 ± 14 67	0.5 0.6
European ancestry African ancestry Body mass index — ko/m ²	67 28 29.8 ± 8.0	68 26 31.7 ± 8.6	0.7 0.6 0.005
Blood pressure — mm Hg Systolic Diastolic	125 ± 15 76 ± 11	124 ± 14 76 ± 10	0.4 0.4
Lung functions Forced expiratory volume in 1 second — % predicted Forced vital capacity —% predicted	74 ± 22 87 ± 20	74 ± 20 85 ± 17	0.9 0.3
FEV ₁ /FVC Asthma control test [†] White blood cells — x10 ⁹ /liter	0.70 ± 0.11 17.4 ± 5.2 7.1 ± 2.5	0.71 ± 0.12 16.8 ± 4.9 7.5 ± 3.0	0.3 0.3 0.08
Neutrophils Eosinophils IgE — IU/ml	4.3 ± 2.2 0.26 ± 0.24 360 ± 677	4.6 ± 2.7 0.25 ± 0.20 336 ± 765	0.11 0.5 0.6
mtDNA-CN Unadjusted mtDNA-CN residuals Adjusted mtDNA-CN residuals	35.8 ± 18.9 -0.747 ± 0.278 -0.947 ± 0.312	178.4 ± 70.7 1.350 ± 1.040 1.347 ± 1.024	<0.0001 <0.0001 <0.0001

Mean ± SD; *P value for Q4 vs. Q1 of adjusted mtDNA-CN. [†]Scores of 19 or higher are well controlled.

Table E5. Cutoff values for mtDNA-CN and other biomarkers with the exacerbation risk in asthmatics in SARP

Exacerbations 1 – 2 vs. 0					Exacerbations ≥ 3 vs. 0									
Variables	OR1	LR1	UR1	<i>P</i> 1	OR2	LR2	UR2	P2	Area under the ROC Curve	Optimal cutoff	OR3	LR3	UR3	P3
Eosinophils— x10 ⁹ /liter	1.093	0.872	1.369	0.441	1.447	1.144	1.832	0.002	0.602	0.338	3.073	1.730	5.459	0.000
lgE — IU/ml	0.883	0.699	1.114	0.294	0.781	0.538	1.134	0.194	0.600	45.000	0.420	0.234	0.757	0.004
Superoxide dismutase — U/ml Fractional	0.971	0.785	1.201	0.787	0.909	0.678	1.218	0.521	0.499	25.694	1.506	0.826	2.746	0.181
exhaled nitric	1.137	0.905	1.429	0.269	1.387	1.090	1.764	0.008	0.589	27.500	2.134	1.213	3.755	0.009
oxide — ppb mtDNA-CN Adjusted mtDNA-CN	0.988 0.997	0.808 0.813	1.209 1.222	0.909 0.980	0.456 0.442	0.239 0.224	0.869 0.875	0.017 0.019	0.614 0.615	55.754 -0.033	0.333 0.352	0.173 0.164	0.642 0.753	0.001 0.007

OR, odds ratio for exacerbation risk of asthma. LR and UR for upper and lower values of 95% confidence interval (CI). P value for the probability.

Table E6. Features of study participants who are divided by above and below mtDNA-CN cutpoint (-0.033) in SARP

Characteristics	Below (<i>n</i> = 794)	Above (<i>n</i> = 445)	P Value [*]
Severe asthmatics — %	46.1	43.3	0.3
Age — yr	42 ± 14	40 ± 15	0.04
Female — %	65	67	0.5
Ancestry — % European ancestry African ancestry Body maga index kg/m ²	65 27 20 8 + 8 4	66 26 21 6 + 8 4	0.7 0.8
Blood pressure — mm Hg	30.8 ± 8.4	31.6 ± 8.4	0.2
Systolic	125 ± 15	123 ± 14	
Diastolic Lung functions Forced expiratory volume in 1 second — % predicted	77 ± 10 74 ± 21	76 ± 9 74 ± 20	0.5 0.6
Forced vital capacity —% predicted	86 ± 19	86 ± 18	0.9
FEV ₁ /FVC	0.69 ± 0.12	0.70 ± 0.12	0.18
White blood cells — x10 ⁹ /liter Neutrophils	7.2 ± 2.4 4.3 ± 2.0	7.5 ± 2.8 4.5 ± 2.4	0.13 0.09 0.3
Eosinophils	0.28 ± 0.25	0.26 ± 0.22	0.2
IgE — IU/mI	336 ± 713	331 ± 682	0.8
mtDNA-CN	51 2 + 23 4	149 8 + 74 2	<0.0001
Unadjusted mtDNA-CN residuals	-0.520 ± 0.359	0.930± 1.092	<0.0001
Adjusted mtDNA-CN residuals	-0.534 ± 0.395	0.954± 1.042	<0.0001

Mean ± SD; **P* value for Above vs. Below adjusted mtDNA-CN cutoff value of -0.033. †Scores of 19 or higher are well controlled.

Supplementary Figures



Figure E1. Severe asthmatics have significantly lower mtDNA-CN than non-severe asthmatics in the Severe Asthma Research Program (SARP). (*A*) Lower mtDNA-CN in severe asthmatics by sex. Lower p-values from comparison of non-severe vs severe asthma overall, in females, and in males. Upper p-value from comparison of all females vs all males. (*B*) Lower mtDNA-CN in severe asthmatics by ancestry. Lower p-values from comparison of non-severe vs severe asthmatics by ancestry, and individuals of other ancestries. Upper p-value from comparison of ancestry.



Figure E2. Odds ratio of risk of three or more exacerbations by quantile of adjusted mtDNA-CN in asthmatics in SARP.



1.137 (0.905 - 1.429)

10

0.2

A Zero vs. one or two exacerbations per SD increase in biomarker

Fractional exhaled nitric oxide

B Zero vs. three and more exacerbations per SD increase in biomarker

0.1



1.0

Figure E3. Associations of adjusted mtDNA-CN and other biomarkers with the exacerbation risk in asthmatics in SARP. (*A*) Zero exacerbations *vs.* one or two exacerbations per SD increase in biomarker. (*B*) Zero exacerbations *vs.* three and more exacerbations per SD increase in biomarker.

Supplemental References

- E1. Longchamps RJ, Yang SY, Castellani CA, Shi W, Lane J, Grove ML, et al. Genome-wide analysis of mitochondrial DNA copy number reveals loci implicated in nucleotide metabolism, platelet activation, and megakaryocyte proliferation. *Hum Genet* 2022; 141: 127-146.
- E2. Falaschetti E, Laiho J, Primatesta P, Purdon S. Prediction equations for normal and low lung function from the Health Survey for England. *Eur Respir J* 2004; 23: 456-463.
- E3. Shrine N, Portelli MA, John C, Soler Artigas M, Bennett N, Hall R, et al. Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study. *Lancet Respir Med* 2019; 7: 20-34.
- E4. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000; 162: 2341-2351.
- E5. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J* 2014; 43: 343-373.
- E6. Dweik RA, Sorkness RL, Wenzel S, Hammel J, Curran-Everett D, Comhair SA, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. *Am J Respir Crit Care Med* 2010; 181: 1033-1041.